DDInter1042 DDInter448
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers robust effectiveness in treating NSCLC in patients with this type of rearrangement. Crizotinib was the first-in-class drug used to treat ALK-positive tumors. Second- and third-generation ALK-tyrosine kinase-inhibitors have overcome many of the pharmacodynamic and genetic resistance mechanisms crizotinib is prone to. Crizotinib was approved by the FDA in 2011, and its use is accompanied by FDA-approved tests used to detect ALK and ROS1 rearrangements.
Crizotinib {u} (Compound) treats {v} (Disease) lung cancer
Crizotinib {u} (Compound) binds {v} (Gene) MET
Crizotinib {u} (Compound) upregulates {v} (Gene) COL11A1
Crizotinib {u} (Compound) is included by {v} (Pharmacologic Class) Organic Cation Transporter 2 Inhibitors
Crizotinib {u} (Compound) downregulates {v} (Gene) WDR77
Crizotinib {u} (Compound) causes {v} (Side Effect) Dizziness postural
Crizotinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Crizotinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Fedratinib
Crizotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Enfortumab vedotin
Crizotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gefitinib
Crizotinib (Compound) treats lung cancer (Disease)
Crizotinib (Compound) binds MET (Gene)
Crizotinib (Compound) upregulates COL11A1 (Gene)
Crizotinib (Compound) is included by Organic Cation Transporter 2 Inhibitors (Pharmacologic Class)
Crizotinib (Compound) downregulates WDR77 (Gene)
Crizotinib (Compound) causes Dizziness postural (Side Effect)
Crizotinib may cause a minor interaction that can limit clinical effects when taken with Modafinil
Crizotinib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin
Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib